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ABSTRACT 
The Epstein-Barr virus (EBV) is found almost exclusively in the activated B cell (ABC) subtype 
of diffuse large B cell lymphoma (DLBCL), yet its contribution to this tumour remains poorly 
understood. We have focussed on the EBV-encoded latent membrane protein-1 (LMP1), a 
constitutively activated CD40 homologue expressed in almost all EBV-positive DLBCL and 
which can disrupt germinal centre (GC) formation and drive lymphomagenesis in mice. 
Comparison of the transcriptional changes that follow LMP1 expression with those that 
follow transient CD40 signalling in human GC B cells enabled us to define pathogenic targets 
of LMP1 aberrantly expressed in ABC-DLBCL. These included the down-regulation of S1PR2, 
a sphingosine-1-phosphate (S1P) receptor that is transcriptionally down-regulated in ABC-
DLBCL, and when genetically ablated leads to DLBCL in mice. Consistent with this we found 
that LMP1-expressing primary ABC-DLBCL were significantly more likely to lack S1PR2 
expression than were LMP1-negative tumours. Furthermore, we showed that the down-
regulation of S1PR2 by LMP1 drives a signalling loop leading to constitutive activation of the 
phosphatidylinositol-3-kinase (PI3-K) pathway. Finally, core LMP1-PI3-K targets were 
enriched for lymphoma-related transcription factors and genes associated with shorter 
overall survival in patients with ABC-DLBCL. Our data identify a novel function for LMP1 in 
aggressive DLBCL. 
 
KEY WORDS: S1P, S1PR2, EBV, LMP1, CD40 and DLBCL 
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INTRODUCTION 
Diffuse large B cell lymphoma (DLBCL) is molecularly and clinically heterogeneous even 
within the activated B-cell (ABC) and germinal center B-cell (GCB) subtypes [1, 2]. Around 
one-third of patients have refractory disease or will relapse, and outcome generally is poor 
for these patients [3]. DLBCL is dependent upon de-regulated cellular signalling, including 
PI3-K/AKT and NF-Ů pathways. Different cell-of-origin (COO) subtypes are addicted to 
different branches of the PI3-K signalling pathway; AKT signalling is critical for the survival of 
PTEN-deficient GC-DLBCL, whereas PI3-<ɲ ?ɷ induces activation of pro-survival NF-Ů
signalling in ABC-DLBCL [4].  
EBV-positive DLBCL accounts for around 10% of cases and is almost exclusively of ABC 
subtype. Although frequently observed against a background of immune impairment, EBV-
positive DLBCL also arises without a prior history of immune suppression; particularly in 
older people, where senescence of the EBV-specific immune response is suspected [5]. 
However, EBV-positive DLBCL occurs also in apparently immunocompetent younger patients 
[6, 7]. Patients with EBV-positive DLBCL have an inferior clinical course and shorter overall 
survival compared with patients with EBV-negative DLBCL; an effect that is particularly 
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consistent among elderly patients even after adjustment for the adverse effects of age [8
10]. 
The EBV-encoded LMP1 is a homologue of the cellular CD40 receptor and is expressed in 
most EBV-positive cases of DLBCL [7]. However, unlike CD40, the spontaneous 
oligomerisation of LMP1s transmembrane domains delivers a constitutive signal. LMP1 is 
essential for the in vitro transformation of B cells by EBV and can block GC formation and 
induce B cell lymphomas in transgenic mice [11, 12]. It is the constitutive nature of the 
LMP1 signal that is transforming. Thus, the B cell-specific expression of a constitutively 
active CD40 receptor, comprising the transmembrane domains of LMP1 and the cytoplasmic 
tail of CD40 leads to lymphoma development in mice, whereas a chimera of the 
transmembrane domains of CD40 and the cytoplasmic region of LMP1 is not transforming 
[13, 14]. While LMP1 constitutively activates both the PI3-K/AKT and the NF-Ů pathways, 
how LMP1 contributes to the pathogenesis of ABC-DLBCL has yet to be established [1517].  
Here we identified genes regulated by LMP1, but not by a transient CD40 signal, in primary 
GC B cells. Putative pathogenic targets of LMP1 included S1PR2, a sphingosine-1-phosphate 
(S1P) receptor that has been shown to be transcriptionally silenced in ABC-DLBCL and when 
genetically ablated to lead to DLBCL-like tumours in transgenic mice [18-23]. We found that 
LMP1-mediated loss of S1PR2 expression initiates a signalling loop leading to the 
constitutive activation of the PI3-K pathway. Moreover, core LMP1-regulated PI3-K target 
genes were enriched for lymphoma-related transcription factors and genes associated with 
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shorter overall survival in patients with ABC-DLBCL. Our data identify novel functions for 
LMP1 in driving aberrant cell signalling and gene expression in aggressive ABC-DLBCL. 
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MATERIALS AND METHODS 
Cells and tissues 
Tonsils and tumour samples were obtained with informed consent and ethical approval 
(REC_RG_HBRC_12-071, REC reference 15/NW/0079; IRAS project ID:171283). Primary GC B 
cells were isolated from tonsils as described [24, 25]. HT [26], SUDHL4 [26], SUDHL6 [26], 
BJAB [27], OCI-Ly1 [28] are EBV-negative GCB-DLBCL lines, Farage [29] is an EBV-positive 
GCB-DLBCL line. OCI-Ly3 [28], OCI-Ly18 [28] and U2932 [30] are EBV-negative ABC-DLBCL 
lines. DG75 [31] is an EBV-negative Burkitt lymphoma line. L591 [32] is an EBV-positive 
Hodgkin lymphoma line. Cell lines were purchased from DSMZ (Braunschweig, Germany), 
OCI (Toronto,ON, Canada) or ATCC (Manassas, VA, USA). Cells were cultured at 37 °C/5% 
CO2 in RPMI1640 or IMDM (for OCI-Ly1, OCI-Ly3, OCI-Ly18), supplemented with 10% fetal 
bovine serum (FCS) and 1% penicillin-streptomycin stock (ThermoFisher Scientific, Waltham, 
MA, USA). 
 
Cell transfections and treatments 
GC B cells were nucleofected (Lonza, Slough, UK), cultivated for 16 h and enriched as 
described previously [24, 25]. SUDHL4, DG75, OCI-ly1 and U2932 cells were nucleofected. 
BJAB cells were electroporated (Bio-Rad Laboratories, Hemel Hempstead, UK) and enriched 
as described [33, 34]. Cells were harvested for RNA extraction, protein extraction or 
immunofluorescence 24 h after transfection. Dual luciferase reporter gene assays (Promega 
Corporation, Southampton, UK) using pGLS1PR2luc promoter were performed as described 
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[24]. Cloning of the S1PR2 promoter fragment and all plasmid details are presented in 
supplementary material, Supplementary materials and methods.  
For CD40 stimulation, cell lines and GC B cells from 9 donors were seeded at 2x10
6
/ml and 
cultivated in the presence or absence/control of 200 ng/ml CD40L (Autogen Bioclear, Calne, 
UK) for indicated times. For PI3-K/AKT inhibition, 5 µM Ly294002 (Pan-PI3-K inhibitor), CAL-
101 (p110-ɷŝnhibitor), MK-2206 (Pan-AKT inhibitor) or DMSO were added after transfection 
and cells cultivated for 2448 h.  
 
Quantitative RT-qPCR  
RNA was isolated using RNeasy® Mini/Micro Kit (QIAGEN, Crawley, UK) and amplified as 
described [24, 25]. CDNA was synthetized using M-MLV Reverse Transcriptase kit 
(Invitrogen, ThermoFisher Scientific). Relative mRNA levels were determined in triplicate 
using real-time fluorimetric measurement of cDNA and comparative CT method. RT-qPCR 
assays are detailed in supplementary material, Table S1A. 
 
Global gene expression analysis 
Tonsillar GC B cells of 9 individuals were cultivated in the presence or absence of CD40L for 
3 h. Extracted RNA was labelled and hybridized to Affymetrix Human Genome U133A 2.0+ 
Arrays. Scanned images of microarray chips were analysed with GeneChip Operating 
Software and Expression Console with target signal set to 100. Probe level quantile 
normalisation and robust multi-array analysis on the raw CEL files were performed with affy 
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package of the Bioconductor project (http://www.bioconductor.org) [35, 36]. Differentially 
expressed probe sets were identified using limma with false discovery rate adjusted p value 
<0.05 [37]. The primary data are available in GEO (http://www.ncbi.nlm.nih.gov/geo/; 
accession no. GSE96709). Gene ontology (GO) analysis was performed using the DAVID 
Gene Functional Classification Tool (http://david.abcc.ncifcrf.gov).   
Analysis of publicly available datasets 
Probe level quantile normalisation was performed as above on datasets GSE10846 [38], 
GSE12453 [39], GSE94610 [40] and GSE10821 [24]. Differentially expressed probe sets were 
identified using limma (p value <0.05, fold-change >1.5) [37]. RNA-seq data from human 
DLBCL were downloaded in April 2016 from the controlled access area of the NIH database 
of genotypes and phenotypes (dbGap; http://www.ncbi.nlm.nih.gov/gap) using accession 
number phs000532 [41, 42].
 
RNA-seq data for four GC B cell samples were from GSE45982: 
GSM1129344, GSM1129345, GSM1129346 and GSM1129347 [43]. RNA-seq data were 
aligned to hg19 human genome using Rsubread aligner and assigned to individual genes 
with featureCounts function [44]. Read counts were normalized between samples and 
converted to counts-per-million (CPM) reads for each gene by edgeR package [45]. 
Differentially expressed genes were identified using edgeR with criteria of CPM>1 in at least 
four samples, p<0.05, fold-change>2.0. To identify genes differentially expressed in DLBCL, 
we compared gene expression in primary DLBCL with that in normal GC B cells. Kaplan-
Meier analyses with samples split by median expression value were performed using the 
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survival package in R. P-values were calculated using the log-rank test. A list of shared NF-
Ů and PI3-K targets in ABC-DLBCL were taken from Kloo et al [40]. 
 
Protein analysis and in situ hybridization 
Protein expression was analysed by immunohistochemistry (IHC), immunoblotting and flow 
cytometry [34]. IHC was carried out using citrate antigen retrieval and H2O2 and 5x casein or 
background reducing reagent (S3022; Dako, Ely, UK) blocking before adding primary 
antibodies in PBS (listed in supplementary material, Table S1B) and visualisation using 
diaminobenzidine (Vector Laboratories, Peterborough, UK) with haematoxylin counterstain. 
An Opal 3-Plex Kit was used for multiplex immunofluorescence (IF) (PerkinElmer, Seer 
Green, UK; NEL791001KT) [46]. Antibody stripping by microwaving in pH 6 citrate buffer was 
used between steps. Omission of individual antibodies was used to assess adequate 
stripping. Slides were scanned using a Vectra 3.0.3 System for detection of cyanine 5, 
cyanine 3, DAPI, texas red and fluorescein. Multispectral images were analysed using InForm 
Automated Image Analysis software version 2.2.1. Images were acquired using an Olympus 
BX-51WI microscope (Olympus, Tokyo, Japan) with 10x, 20x and 40x objective lenses. 
Comparisons of marker expression were performed using Pearsons Chi-squared test with 
Yates' continuity correction. EBV status was assessed by EBER in situ hybridisation [47].  
 
Statistics 
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Statistical tests are indicated in the relevant sections. All experiments were performed at 
least in triplicate, and for human tonsillar B cells on at least three separate donors. Tests 
were considered statistically significant if p<0.05. 
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RESULTS 
Identification of putative pathogenic LMP1 targets in DLBCL 
To identify pathogenic targets of LMP1, we compared the transcriptional effects of this viral 
oncogene with those of its physiological homologue, CD40, in primary human GC B cells. To 
identify CD40 targets, tonsillar GC B cells were stimulated with 200 ng/ml CD40L for 3 h, a 
time-point optimized to give maximal regulation of known CD40 targets in preliminary 
experiments (not shown) [24, 25, 48]. To reduce the effects of inter-donor variation, 
stimulation of the CD40 receptor was performed on 9 separate donors and the mean 
expression of each gene across all donors calculated. To define LMP1 targets, we re-
analysed our previous microarray dataset describing the transcriptional effects of LMP1 in 
GC B cells [24]. Of the 767 genes up-regulated and 1435 genes down-regulated by CD40 
(supplementary material, Table S2A,B), 224 and 429 genes were also up- and down-
regulated, by LMP1, a statistically significant overlap that confirms the partially overlapping 
functions of LMP1 and CD40 in B cells (Figure 1A; p<0.0001). Although aberrantly regulated 
CD40 targets might also contribute to the pathogenesis of DLBCL, our primary interest was 
in those LMP1 targets not regulated by CD40 (supplementary material, Table S2C,D). We 
found that genes regulated by LMP1, but not CD40, were significantly enriched in the set of 
genes concordantly differentially-expressed when primary DLBCL were compared to normal 
GC B cells in our re-analysis of published gene expression dataset (Figure 1A; p<0.0001; 
supplementary material, Table S2EH) [39]. We also observed a significant enrichment of 
LMP1 targets among genes shown to be differentially expressed when the ABC- (Figure 1B; 
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p<0.0001) and EBV-positive (not shown; p<0.0001) subtypes of DLBCL were compared 
separately to normal GC B cells (supplementary material, Table S3AD) [41-43]. RT-qPCR 
confirmed the regulation of selected genes; notably, they included sphingosine kinase 1 
(SPHK1), which encodes the enzyme responsible for sphingosine-1-phosphate (S1P) 
production (Figure 1C).  
 
LMP1, but not CD40, down-regulates expression of sphingosine-1-phosphate receptor 2 
(S1PR2)  
LMP1 target genes included S1PR2, which encodes an S1P receptor that has been shown to 
be transcriptionally down-regulated in ABC-subtype DLBCL, and which, when genetically 
ablated, induces DLBCL in mice [18-20, 23]. RT-qPCR confirmed that S1PR2 expression was 
down-regulated by LMP1, but not CD40, in GC B cells (Figure 2A). We next studied the 
regulation of S1PR2 by LMP1 in SUDHL4 and OCI-Ly1 GCB-DLBCL cell lines which have high 
S1PR2 expression (supplementary material, Figure S1). LMP1 expression, but not CD40 
stimulation, significantly decreased S1PR2 mRNA expression in both lines (Figure 2B). To 
rule out the possibility that CD40 might regulate S1PR2 at the later time points, we 
performed CD40 stimulation also for 6 h and 24 h, but observed no significant change in 
S1PR2 levels (Figure 2B). Furthermore, we confirmed that the CD40 signalling pathway was 
intact in the cell lines used, since we could induce expression of CD40 targets, including 
ICAM1 (supplementary material, Figure S2A), which we have previously shown is also an 
LMP1 target and which was significantly induced following the stimulation of GC B cells by 
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CD40 [24]. As a further a control we measured S1PR2 expression following the addition of 
CD40L to mock electroporated cells. We did not observe any decrease in S1PR2 levels, in 
contrast to the levels of ICAM1 which were increased, as expected (data not shown). To 
show that the S1PR2 downregulation is mediated by the constitutive signal induced by the 
membrane part of LMP1, we used an expression vector that contains the cytoplasmic 
signalling domain of CD40 fused to the transmembrane domain of LMP1 [14]. This fusion 
protein provides a constitutive CD40 signal to the cell. We found that this constitutive CD40 
signal leads, like LMP1, to the downregulation of S1PR2 in B cell lymphoma lines 
(supplementary material, Figure S2B). Next, we used multiplex IF to investigate the impact 
of LMP1 on S1PR2 protein levels in SUDHL4 cells which show high levels also of S1PR2 
protein (not shown). SUDHL4 cells ectopically expressing LMP1 were significantly more likely 
to lack S1PR2 protein than un-transfected LMP1-negative cells in the same population 
(Figure 2C). As a control, we showed that LMP1 significantly increased ICAM1 expression in 
SUDHL4 cells (Figure 2C). To show that the down-regulation of S1PR2 protein by LMP1 was 
not an artefact associated with transfection, we stained Farage and L591 which are EBV-
positive lymphoma cell lines that endogenously express LMP1. Compared with their LMP1-
negative counterparts, significantly more LMP1-positive Farage cells and L591 cells were 
S1PR2-negative (Figure 2C, lower right panels). These effects appear to be predominantly 
mediated at the level of the S1PR2 promoter, since we showed that LMP1 significantly 
reduced S1PR2 promoter activity in the BJAB and DG75 lines which show robust effects in 
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luciferase assays (Figure 2D). We conclude that LMP1, but not its physiological homologue 
CD40, down-regulates S1PR2 expression in B cells. 
 
Down-regulation of S1PR2 in LMP1-expressing primary DLBCL 
Next, we studied the expression of S1PR2 mRNA in primary DLBCL. Re-analysis of two large 
expression datasets confirmed the down-regulation of S1PR2 in DLBCL compared to normal 
GC B cells, and showed that this was particularly pronounced in ABC-DLBCL (Figure 3A) [38, 
41-43]. To study the relationship between the expression of S1PR2 and LMP1 in primary 
tumours we performed IHC using an antibody that we previously showed is specific for 
S1PR2 [46]. In contrast to GC B cells which expressed S1PR2, 114/167 DLBCL showed no 
tumour cell S1PR2 expression (Figure 3B). We stained all cases for BCL6, CD10 and IRF4 and 
defined each as either GCB or non-GCB type using the Hans algorithm [49]. 14 cases, all non-
GCB type, were EBER-positive, 10 of these were LMP1-positive. EBER-positive and LMP1-
positive non-GC cases were significantly more likely to be S1PR2-negative compared with 
EBER-negative and LMP1-negative non-GCB cases (p<0.05 for both comparisons; 
supplementary material, Table S4). Moreover, a meta-analysis of eleven different DLBCL 
gene expression datasets [50] (supplementary material, Table S5) revealed an inverse 
relationship between genes regulated by S1PR2 and LMP1. Thus, genes negatively 
correlated (OR=3.4; p<0.0001), but not those positively correlated (OR=0.69; p=0.43), with 
S1PR2 were significantly enriched among genes up-regulated by LMP1 in primary DLBCL. 
Likewise, genes positively correlated with S1PR2 were significantly enriched (OR=10.79; 
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p<0.0001), and those negatively correlated with S1PR2 significantly depleted (OR=0.42; 
p<0.001), from those down-regulated by LMP1. 
 
LMP1-mediated down-regulation of S1PR2 promotes constitutive PI3-K signalling in DLBCL 
Having shown that S1PR2 expression is frequently lost in LMP1-positive ABC-DLBCL, we next 
explored the mechanism responsible for this effect, focussing on PI3-K signalling. Consistent 
with previous reports, we found that LMP1 increased the phosphorylation of the PI3-K 
downstream target, AKT, in the B cell lines (Figure 4A) [15]. To study if PI3-K/AKT was 
responsible for S1PR2 down-regulation, we transfected SUDHL4 cells with a plasmid 
expressing a MYC-tagged constitutively active AKT1 gene (MYC-caAKT1) and measured 
S1PR2 protein levels by multiplex IF. Induction of pAkt in SUDHL4 cells following MYC-
caAKT1 transfection significantly decreased the numbers of cells expressing S1PR2 
(p<0.0001; Figure 4B). To determine if the down-regulation of S1PR2 by PI3-K/AKT was at 
the promoter level, we repeated transfections, also using a plasmid expressing a 
constitutively active p110 (PI3-K catalytic subunit) and performed S1PR2 promoter assays. 
The ectopic expression of LMP1, MYC-caAKT1 and p110 significantly inhibited S1PR2 
promoter activity (Figure 4C). Conversely, the inhibition of PI3-K significantly increased 
S1PR2 promoter activity in LMP1-transfected, and in control-transfected, DLBCL cell lines 
(Figure 4D). To show a relationship between S1PR2 expression and PI3-K signalling also in 
primary DLBCL, we re-analysed published data on the transcriptional effects of the PI3-K 
inhibitor, 15e on the ABC cell line, HBL1 [40]. We found that genes regulated by LMP1 and 
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correlated with S1PR2 in DLBCL were significantly enriched for genes concordantly regulated 
by PI3-K in HBL1 cells (p<0.0001; supplementary material, Table S6A,B).  
S1PR2 itself can also inhibit AKT activity in mouse B cells [18]. We investigated if this was 
also the case in DLBCL. Re-expressing S1PR2 in U2932 cells, an ABC line with low 
endogenous S1PR2 levels, reduced AKT phosphorylation (Figure 4E). Gene editing of both 
alleles of S1PR2 in SUDHL4 cells (supplementary material, Figure S3A,B), which have wild-
type S1PR2, GNA13, P2YR8 and ARHGEF1 genes and therefore intact S1PR2 signalling [41, 
42] also increased AKT phosphorylation (Figure 4F). Therefore, loss of S1PR2 expression can 
itself further increase PI3-K activity. Thus, our data reveal a signalling loop which acts to 
sustain PI3-K signalling in DLBCL (Figure 4G). 
 
LMP1-regulated PI3-K targets are enriched for lymphoma-associated transcription factors 
and associated with shorter survival in ABC-DLBCL 
Integration of the different gene expression datasets enabled us to identify a core set of 41 
genes concordantly regulated by LMP1 and PI3-K signalling and significantly and inversely 
correlated with S1PR2 expression in DLBCL (p<0.0001; Figure 5A). These included S1PR2 
itself, as expected. GO analysis revealed that this core set was significantly enriched for 
transcription factors (Figure 5B), including ATF3, BATF and BATF3 which were up-regulated, 
and BCL6, BPTF, KLF12, and MEF2C which were down-regulated, by LMP1. RT-qPCR 
confirmed the down-regulation of BCL6, BPTF, KLF12 and MEF2C by LMP1 (Figure 5C) and by 
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AKT1 (supplementary material, Figure S4A). BCL6, KLF12, and MEF2C were also up-regulated 
following the treatment of control or LMP1-transfected cells with the pan-PI3-K Ly294002, 
the p100-Ⱦ-specific CAL-101 and the pan-AKT MK-2206 inhibitors (supplementary material, 
Figure S4B).  
Re-analysis of published global gene expression data confirmed that the transcription 
factors in our core set were also concordantly differentially expressed in ABC-DLBCL 
(supplementary material, Figure S5A,B). Using IHC and commercially available antibodies 
suitable for FFPE tissues, we confirmed the increased expression of BATF and BATF3, and 
the decreased expression of two transcription factors; MEF2C and KLF12, not previously 
described before in ABC-DLBCL (Figure 5D).  
Finally, we explored the overlap of LMP1-PI3-K targets with genes associated with clinical 
outcome in DLBCL. Re-analysing the dataset reported by Lenz et al [38], but confining our 
analysis to only those patients with ABC-DLBCL treated with R-CHOP, the current standard-
of-care treatment, we found that genes down-regulated by LMP1-PI3-K, including MEF2C 
and KLF12, were significantly enriched among genes for which lower expression was 
associated with poorer overall survival (p=0.0011; Figure 5E).  
We conclude that LMP1 and PI3-K regulate a core set of B cell-associated transcription 
factors, including several not previously described in ABC-DLBCL that are associated with 
shorter overall survival in patients with ABC-DLBCL.  
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DISCUSSION 
We have compared the transcriptional effects of the EBV-encoded LMP1, with that of its 
physiological homologue, CD40, in normal human GC B cells to identify the oncogenic 
effects of LMP1 relevant to the pathogenesis of DLBCL. We used GC B cells because they are 
the cell type readily isolatable from tonsils which are the nearest equivalent to the stage of 
B cell differentiation from which ABC-type DLBCL is believed to derive. We found that LMP1, 
but not CD40, down-regulated the expression of S1PR2, a G-protein-coupled receptor that 
binds the bioactive sphingolipid metabolite S1P, and which signals through its ability to 
couple to the small 'ƉƌŽƚĞŝŶƐ ?'ɲ ? ?ĂŶĚ'ɲ ? ?[51]. Although we used soluble CD40L, which 
is considered to provide a relatively weak CD40 signal compared to the membrane bound 
trimeric forms of CD40L, Basso et al, reported the effects of trimeric CD40L (NIH3T3mCD40L 
cells) on B cells and also did not observe any downregulation of S1PR2 even after 24 h of 
stimulation [52].  
Our IHC studies also revealed for the first time the loss of S1PR2 protein expression in 
DLBCL. Moreover, LMP1-expressing ABC-DLBCL were significantly more likely to lack tumour 
cell expression of S1PR2 than were LMP1-negative cases suggesting that LMP1 is important 
for the down-regulation of S1PR2 in EBV-positive primary DLBCL. S1PR2 is critical for the 
maintenance of normal GC integrity. For example, in mice, S1PR2 deficiency leads to the 
increased survival and migration of GC B cells in response to antigen stimulation, resulting in 
enlarged and less well-defined GC [18]. Thus, the down-regulation of S1PR2 by LMP1 might 
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also explain the previous observation that unlike CD40, LMP1 disrupts normal GC formation 
in transgenic mice [12].  
Several lines of evidence show that S1PR2 is a tumour suppressor in B cells. For example, 
S1PR2 deficient mice have an increased propensity to develop lymphomas that resemble 
human DLBCL [20]. Furthermore, ectopic expression of S1PR2 has been shown to induce 
apoptosis in DLBCL cell lines; an effect that was equally efficient in both GCB and ABC-
derived lines [22]. S1PR2 can also suppress the outgrowth of xenografts of DLBCL cells in 
immuno-deficient mice, and its loss accelerates MYC-driven lymphoma development in mice 
[22].  
Our data support the existence of an alternative pathway to inactivate S1PR2 in DLBCL. 
Thus, in GCB-DLBCL, S1PR2 signalling is silenced primarily by mutations in S1PR2 itself, or by 
mutations or methylation of other genes involved in S1PR2 signalling, including GNA13, 
ARHGEF1 and P2RY8 [1821, 41]. In contrast, in ABC-DLBCL, S1PR2 inactivation appears to 
occur primarily as a consequence of transcriptional down-regulation. In some cases this is 
mediated by over-expression of the FOXP1 transcription factor [22]. Our data reveal that 
LMP1 is another upstream repressor of S1PR2 transcription important for the EBV-positive 
forms of ABC-DLBCL. The regulation of S1PR2 by LMP1 may be independent of FOXP1 since 
it has been shown that FOXP1 mRNA levels are lower in EBV-positive compared with EBV-
negative DLBCL [53]. In keeping with this we observed either no change or only a modest 
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up-regulation of FOXP1 mRNA following LMP1 expression in different B cell lymphoma cell 
lines (supplementary material, Figure S6).  
We showed that the transcriptional down-regulation of S1PR2 or its knock out by 
CRISPR/Cas9 increased PI3-K signalling in DLBCL. Moreover, we showed that the 
transcription of S1PR2 itself can be suppressed by the activation of either PI3-K or AKT. 
Thus, our data support a model in which the transcriptional down-regulation of S1PR2 is 
sufficient to activate the PI3-K/AKT pathway, in turn initiating a signalling loop leading to 
further loss of S1PR2. Our data also suggest that in EBV-positive cases of DLBCL, this 
signalling loop is likely to be driven by the EBV oncoprotein, LMP1. Our data do not agree 
with the findings of Flori et al [22] who showed no effect of the ectopic expression of S1PR2 
on AKT phosphorylation in DLBCL cell lines, including U2932, used in our study. We observed 
robust decreases in AKT phosphorylation in U2932 cells transfected with S1PR2, but not at 
the later time points (>48 h) when there were substantially reduced numbers of S1PR2-
transfected compared to vector-transfected cells (not shown); presumably reflecting the 
well-described negative effect of S1PR2 on cell survival.  
Dependency on PI3-K signalling for survival is apparent in both COO subtypes, but is driven 
by different molecular abnormalities [54, 55]. Thus, PTEN loss is an important mechanism of 
PI3-K/AKT activation in some GCB-DLBCL. In contrast, ABC-DLBCL cells are not dependent 
upon AKT signalling for survival, but require the PI3-K mediated induction of NF-Ů
activation [40, 56]. In keeping with this we observed that the core set of LMP1-PI3-K 
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regulated genes significantly overlapped with NF-Ů ƚĂƌŐĞƚ ŐĞŶĞƐ that were previously 
shown to be dependent upon PI3-K signalling in ABC-DLBCL (OR=38.16; p<0.0001, not 
shown) [40]. Our experiments also revealed that LMP1 can down-regulate S1PR2 in the 
absence of a functional PI3-K pathway, suggesting that NF-ŮŵŝŐŚƚalso directly as well as 
indirectly impact on the down-regulation of S1PR2 expression in ABC-DLBCL. In support of 
this, the S1PR2 promoter contains a number of NF-ŮďŝŶŐŝŶŐƐŝƚĞƐ ?supplementary material, 
Figure S3B).  
In keeping with a previous report [22], we found that low S1PR2 expression was associated 
with significantly reduced overall survival in patients with DLBCL (not shown). However, 
when we refined this analysis we found that this effect was no longer apparent when 
patients were stratified by COO subtype (not shown), presumably because, as we showed 
here, the mRNA levels of S1PR2 are substantially lower in ABC-DLBCL, compared to GCB-
DLBCL. In contrast, while S1PR2 alone had no impact on prognosis in the different COO 
subtypes when analysed separately, we found that among ABC patients receiving R-CHOP 
therapy, the LMP1-driven gene expression signature associated with the concomitant loss of 
S1PR2 and the activation of PI3-K signalling, was enriched among genes associated with 
poor survival. These observations are consistent with reports that PI3-K/AKT signalling 
confers inferior survival in ABC-DLBCL [57] and could explain the reported poorer outcomes 
for patients with EBV-positive DLBCL [5, 6, 8-10]. 
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Several of the transcription factors present in this core signature have to our knowledge not 
previously been reported before in DLBCL. They include BPTF, a c-MYC interactor that is 
required for c-MYC chromatin recruitment and transcriptional activity [58], as well as KLF12 
and MEF2C, which we found to be associated with poor prognosis. KFL12, a member of the 
Kruppel-like family of transcription factors, is a putative tumour suppressor gene that 
regulates anoikis by promoting cell cycle transition through S phase [59]. MEF2C is 
necessary for GC formation [60], and may like its relative MEF2B which is mutated in DLBCL, 
also regulate BCL6 transcriptional activity [61].  Furthermore, we found that low expression 
of KLF12 was associated with poorer overall survival in both RCHOP- and CHOP-treated 
DLBCL patients, whereas low expression of MEF2C was associated with shorter overall 
survival only in RCHOP patients suggesting a possible interaction with rituximab (not 
shown). 
Pharmacological inhibition of PI3-K signalling can suppress lymphoma growth and survival in 
pre-clinical tumour models of DLBCL [4, 40, 55]. For example, the PI3-<ɲ ?ɷ ŝŶŚŝďŝƚŽƌ
AZD8835 has potency in ABC-DLBCL models, whereas the AKT inhibitor AZD5363 induces 
apoptosis in PTEN-deficient DLBCL [4]. Our data suggest that targeting S1P or its receptors 
could provide an alternative approach to suppress aberrant PI3-K signalling in ABC-DLBCL 
patients with deficient S1PR2 expression.  
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FIGURE LEGENDS 
Figure 1. Identification of putative pathogenic LMP1 targets in DLBCL. (A) Comparison of 
the transcriptional targets of LMP1 and CD40 in primary human GC B cells revealed a 
statistically significant overlap (p<0.0001). Moreover, LMP1 target genes were significantly 
enriched in genes concordantly differentially expressed when primary DLBCL was compared 
to normal GC B cells (p<0.0001). Shown here is data from Brune et al. In this dataset DLBCL 
was not split by COO subtype [39]. (B) LMP1 target genes were also significantly enriched in 
genes differentially expressed when ABC-DLBCL was compared to normal GC B cells 
(p<0.0001). This analysis used data from Morin et al (DLBCL) [41, 42] and Beguelin et al (GC 
B cells) [43]. (C) RT-qPCR was used to confirm the regulation of selected genes by LMP1, but 
not by CD40. Data are in triplicate and each is representative of the results of three separate 
donors. TNFAIP3, a known LMP1 and CD40 target, is used as a positive control. Values are 
presented as 2
-ȴȴd
 and relative to a GC B cell control. *denotes p<0.05, **p<0.01, 
***p<0.001 (Students t-test).  
Figure 2. LMP1, but not its physiological homologue CD40, down-regulates the expression 
of S1PR2 in B cells. (A) RT-qPCR analysis of S1PR2 expression in LMP1-transfected and CD40-
stimulated GC B cells. Data presented are triplicates and each is representative of the results 
of three separate donors. Values are presented as 2
-ȴȴd
 relative to GC B controls. **denotes 
p<0.01 (Students t-test). (B) S1PR2 expression measured by RT-qPCR in LMP1-transfected 
or CD40-stimulated DLBCL cell lines, SUDHL4 and OCI-Ly1. Data presented are triplicates and 
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each is representative of the results of three separate biological replicates. Statistics are 
presented as 2
-ȴȴT
 relative to controls. *denotes p<0.05 (Students t test). ns=non-
significant, ns^ indicates no significant down-regulation. (C) Multiplex IF for LMP1 (green) 
and either S1PR2 or ICAM1 (red) in SUDHL4 cells transfected with LMP1. LMP1-positive cells 
(white arrows) were significantly more likely to be S1PR2-negative and ICAM1-positive than 
LMP1-negative cells. Lower panels show the proportions of SUDHL4 cells positive for S1PR2 
or ICAM1 by LMP1 status and data from Farage and L591 cells and are representative of 
three separate biological replicates. Original magnification x600. (D) S1PR2 mRNA (top 
panel) and promoter activity (bottom panel) in LMP1-transfected DG75 and BJAB cells. Data 
are representative of three biological replicates. *denotes p<0.05, ***p<0.001, and 
****p<0.0001 (Students t-test). 
Figure 3. Down-regulation of S1PR2 in LMP1-expressing primary DLBCL. (A) Left panel: 
Significantly lower S1PR2 expression in ABC- and GCB-DLBCL compared with normal GC B 
cells in a re-analysis of existing RNAseq datasets (p<0.0001 and p=0.002 respectively) [41
43]. Right panel: Significantly lower S1PR2 expression in ABC-DLBCL compared with GCB-
DLBCL (p<0.0001) [38]. (B) Top left panel: Normal GC B cells express S1PR2 protein. Top 
middle panel: a case of testicular DLBCL that is negative for S1PR2. Tumour cells are shown 
by the black arrow and positive staining for S1PR2 in normal seminiferous tubules by the 
white arrow. Top right panel: a case of DLBCL that is S1PR2-positive. Bottom left panel: co-
staining for LMP1 (red) and S1PR2 (green) in a representative case of EBV-positive DLBCL 
showing that the LMP1-positive tumour cells are S1PR2-negative (white arrows). A blood 
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vessel is stained for S1PR2. Bottom right panel; a case of LMP1-negative DLBCL expressing 
S1PR2 stained for CD20 (red) and S1PR2 (green). Original magnifications x200 and x600. 
Figure 4. LMP1-mediated down-regulation of S1PR2 promotes constitutive PI3-K/AKT 
signalling. (A) LMP1 increased the phosphorylation of AKT in BJAB and SUDHL4 cells. 
SUDHL4 lysates were from the same experiment in which we had shown that LMP1 down-
regulates S1PR2 expression (Figure 2B; left panel). Levels of each protein are shown in 
LMP1-transfected cells compared with those transfected with empty vector (control). (B) 
SUDHL4 cells were transfected with a plasmid expressing a MYC-tagged constitutively active 
AKT1 and the cells stained for the MYC tag, pAKT and S1PR2 by multiplex IF. Cells 
transfected with the AKT1 plasmid (white arrows) and expressing the MYC-tag (green) were 
significantly more likely to be pAKT-positive (yellow) and to lack expression of S1PR2 (red) 
than were un-transfected cells in the same population (p<0.0001). Original magnification 
x600. (C) S1PR2 promoter activity in BJAB and DG75 cells transfected either with LMP1, a 
constitutively activated AKT1, or a constitutively activated p110. (D) Inhibition of PI3-K 
signalling by LY294002 increased S1PR2 promoter activity in LMP1-transfected and in 
control-transfected B cell lymphomas. (E) Ectopic expression of S1PR2 in U2932 cells 
reduced the levels of phosphorylated AKT. (F) Compared with wild-type controls (designated 
LA2, HB2, HB4), CRISPR/cas9-mediated knockout of S1PR2 in three clones of SUDHL4 cells 
(designated HA1, HA2, HC3) resulted in increased levels of phosphorylated AKT. For all RT-
qPCR, S1PR2 promoter assays and immunoblotting experiments, representative examples of 
three separate biological replicates are shown. *denotes p<0.05, ***p<0.001, and 
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****p<0.0001 (Students t-test). G) Diagrammatic representation of our proposed signalling 
loop driven by LMP1, in which S1PR2 down-regulation activates PI3-K/AKT signalling, in turn 
leading to the further down-regulation of S1PR2 expression. 
Figure 5. LMP1-regulated PI3-K targets are enriched for lymphoma-associated 
transcription factors and associated with shorter overall survival in ABC-DLBCL. (A) 
Identification of a subset of 41 transcriptional targets of LMP1 that were also differentially 
expressed following treatment with a PI3-K inhibitor and anti-correlated with S1PR2 in 
DLBCL, including S1PR2 itself. (B) Gene set enrichment analysis of these genes revealed 
significant enrichment of GO terms associated with transcriptional regulation (asterisks). 
Grey bars show the observed percentage, and black bars the expected percentage of genes 
in a GO category. Transcription factors among the 41 target genes are shown in boxes in A). 
(C) RT-qPCR shows that the down-regulation of S1PR2 by LMP1 in B cell lymphoma cell lines 
was accompanied by the down-regulation of, BCL6, BPTF, KLF12, and MEF2C. Shown are 
data in three cell lines; each is representative of three separate biological replicates. 
*denotes p<0.05, **p<0.01, ***p<0.001 (Students t-test). (D) Representative examples of 
BATF, BATF3, MEF2C and KLF12 staining in normal lymphoid tissues and primary ABC-DLBCL 
(Original magnifications x200 and x600), and right panel, H-scores of these cases confirming 
the up-regulation of BATF and BATF3 and the down-regulation of KLF12 and MEF2C proteins 
in the tumour cells of ABC-DLBCL classified according to the Hans algorithm. (E) Kaplan
Meier curves showing that the down-regulation of MEF2C and KLF12 was associated with 
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significantly reduced overall survival in patients with ABC type DLBCL receiving R-CHOP 
therapy.  
 
 
 
 
 
 
 
 
SUPPLEMENTARY MATERIAL ONLINE 
Supplementary materials and methods  YES 
Supplementary figure legends NO, because legends are embedded in the single Suppl Fig 
PPTX file 
Figure S1. Expression of S1PR2 in DLBCL cell lines 
Figure S2A. Expression of ICAM1 after stimulation of different B cell lymphoma cell lines 
with CD40L 
Figure S2B. Downregulation of  S1PR2 after the expression of a constitutively active CD40 
ǤǤ
  
 
Figure S3A. DNA and protein sequences of three independent CRISPR knockout clones (HA1, 
HA2 and HC3) 
Figure S3B. Predicted transcription factor binding sites in the S1PR2 promoter 
Figure S4A. Regulation of lymphoma-associated transcription factors by PI3-K/AKT signalling 
Figure S4B. Regulation of lymphoma-associated transcription factors by PI3-K/AKT signalling 
Figure S5A. Differential expression of LMP1-regulated transcription factors in primary DLBCL 
(data from Morin et al [41, 42] and Beguelin et al [43]) 
Figure S5B. Differential expression of LMP1-regulated transcription factors in primary DLBCL 
(data from Lenz et al [38]) 
Figure S6. Expression of FOXP1 after transfection of different B cell lymphoma cell lines with 
LMP1 
Table S1A-B. RT-qPCR assays and antibodies used 
Table S2EH. Genes regulated by LMP1 and differentially expressed in DLBCL 
Table S3AD. Genes differentially expressed in DLBCL 
Table S3E,F. Counts for SUDHL4 cells stained with LMP1 and either S1PR2 or ICAM1 
Table S4. Counts for S1PR2, LMP1 and EBER positivity in non-GC cases   
Table S5. Genes correlated with S1PR2 in DLBCL (all significant genes) 
Table S6A,B. Genes differentially expressed in HBL1 cells after treatment with 15e  
 
ǤǤ
 ? ? ? ? ? ? ? ?Ǧ ? ? ? ?	 ?ǡǤ
ǤǤ
 ? ? ? ? ? ? ? ?Ǧ ? ? ? ?	 ?ǡǤ
ǤǤ
 ? ? ? ? ? ? ? ?Ǧ ? ? ? ?	 ?ǡǤ
ǤǤ
 ? ? ? ? ? ? ? ?Ǧ ? ? ? ?	 ?ǡǤ
ǤǤ
 ? ? ? ? ? ? ? ?Ǧ ? ? ? ?	 ?ǡǤ
ǤǤ
